Skip to main content

Higher Risk for Schizophrenia Seen Among Patients With Eczema

Medically reviewed by Drugs.com.

By Lori Solomon HealthDay Reporter

TUESDAY, Aug. 8, 2023 -- Having atopic dermatitis is associated with a higher risk for schizophrenia and schizoaffective disorder, according to a study published online July 26 in the Archives of Dermatological Research.

Ryan Fan, from the Yale School of Medicine in New Haven, Connecticut, and colleagues used electronic health record data from participants in the All of Us research program (13,433 atopic dermatitis cases and 53,732 matched controls) to assess the relationship between atopic dermatitis and schizophrenia and schizoaffective disorder in a nested, matched, case-control study.

The researchers found that participants with atopic dermatitis were more likely to have schizophrenia (2.0 versus 1.1 percent) or schizoaffective disorder (1.8 versus 0.5 percent). Even when controlling for demographics and comorbidities, the association persisted (odds ratios, 1.64 and 2.44 for schizophrenia and schizoaffective disorder, respectively).

"This study provides further strong evidence for a potential relationship between atopic dermatitis with schizophrenia and schizoaffective disorder," the authors write. "Dermatologists treating patients with atopic dermatitis should be aware of these associations to facilitate collaborative management with other providers when appropriate."

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted August 2023

Read this next

SNP rs13194504 AA Genotype Linked to Severity of Tardive Dyskinesia

TUESDAY, June 25, 2024 -- For patients with schizophrenia, the single-nucleotide polymorphism (SNP) rs13194504 AA genotype is associated with reduced severity of tardive...

Lebrikizumab Tied to Sustained Atopic Dermatitis Treatment Effect

TUESDAY, June 18, 2024 -- Lebrikizumab is associated with sustained effects for moderate-to-severe atopic dermatitis for up to week 52 following withdrawal of treatment, according...

Parental E-Cigarette Use Linked to Increase in Pediatric Atopic Dermatitis

TUESDAY, May 28, 2024 -- Parental electronic cigarette use is associated with increased odds of pediatric atopic dermatitis (AD), according to a research letter published online...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.